Skip to main content

Full text of "USPTO Patents Application 10555896"

See other formats


) 




PATENT 

ATTORNEY DOCKET NO. 50125/107001 



Certificate of Mailing: Date of Deposit: March 19. 2008 

I hereby certify under 37 C.F.R. § 1 .8(a) that this correspondence is being deposited with the United States Postal 
Service as first class mail with sufficient postage on the date indicated above and is addressed to Commissioner for 
Patents, P.O. Box 1450, Alexandria, VA 22313-1450. 

Sam Cha _ 



Printed name of person mailing correspondence Sign^type^of pggroh mailing correspondence 




IN THE UNITED STATES PATENT AND TRADEMARK OFFICE 
Applicant: Superti-Fuga et al. Confirmation No.: 2727 

Serial No.: 10/555,896 Art Unit: 1645 

371(c) Date: December 6, 2006 Examiner: Not Yet Assigned 

Customer No.: 21559 

Title: PROCESS FOR THE IDENTIFICATION OF NEW MEDICAL 

TARGETS 

Commissioner for Patents 

P.O. Box 1450 

Alexandria, VA 22313-1450 

PETITION UNDER C.F.R. $ 1 . 1 82 

4 

Applicants petition to have the foreign priority information corrected in the above- 
referenced application. This application is the National Stage of PCT/EP2004/004883. 
International Application No. PCT/EP2004/004883 was filed on May 7, 2004 claiming 
the priority of EP 03 100274.4, allegedly filed on May 7, 2003. This priority information 
was incorrect. The correct priority document should have been EP 03010290.9 filed on 
May 7, 2003 (see, Exhibit 1; Request filed with the European Patent Office (E.P.O.) in 
the corresponding European patent application, EP 04731591.6). 



03/21/E008 EAYALEWl 00000048 10555896 

01 FC:1462 400.00 Gx 



The incorrect priority document, EP 03 100274.4, corresponds to a patent 
application filed on February 10, 2003, relating to completely different subject matter, 
namely to protein complexes of the TNF-a signal transduction pathway. 

The correct priority document, EP 03010290.9 was filed, as correctly indicated in 
the PCT Request, on May 7, 2003. On June 9, 2004, it was requested that the E.P.O. 
prepare and transmit to the International Bureau a certified copy of EP 03100274.4. 

On November 1 1, 2004, more than five months after the filing of the June 9, 2004 
request, and after the 16-month term as set in PCT Rule 26bis, a notification from the 
E.P.O. was received indicating an inconsistency between the filing date and the number 
of the priority document. 

On December 9, 2004, a request for correction of priority in the international phase 
was filed. Since the 16-month deadline for such correction had already passed, this 
request was rejected on February 21, 2005. 

As a result of the above sequence of events, the publication of International 
Application No. PCT/EP2004/004883 (WO 04/099774) lists the incorrect foreign priority 
information (i.e., EP 03100274.4; front page of WO 04/099774 enclosed; Exhibit 2). 
Applicants submit that the correct foreign priority information is listed on the Application 
Data Sheet filed on November 7, 2005 in the above-referenced case: EP 03010290.9 
(Exhibit 3; page 5). 

The Filing Receipt mailed in the present application on August 20, 2007 lists the 
incorrect foreign priority information: EP 03 100274.4. Applicants hereby respectflilly 
request that the enclosed Filing Receipt be corrected as follows. 

Foreign Applications 

EUROPEAN PATENT OFFICE (EPO) 03100274.4 03010290.9 05/07/2003 



2 



Enclosed is a check for $400.00 for the fee required by 37 C.F.R. § 1.17(f). If 
there are any other charges or any credits, please apply them to Deposit Account No. 03- 
2095. 

Respectfully submitted, 

Date: 




Clark & Elbing LLP 
101 Federal Street 
Boston, MA 021 10 
Telephone: 617-428-0200 
Facsimile: 617-428-7045 



3 




De-Docketdd 

JsfT AND TRADEMARK OFFICE 



rage ioij 

RECEIVED 

AUG i 3 200? 



UNITED STATES DEPARTMENT OFCOJ 
United States Patent and 
r: COMMISSIONER FOR 
P.O. Box 1450 

i 22315-1450 



j APPL NO. 


1 FILING OR 371(C) 
I DATE 


ART UNIT 


FIL FEE REC'D 


ATTY.DOCKET NO 


j TOTCLMS | INDCLMS J 


10/555,896 


12/06/2006 


1645 


1380 


50125/107001 


27 1 



21559 

CLARK & ELBING LLP 
101 FEDERAL STREET 
BOSTON, MA 02110 



CONFIRMATION NO. 2727 
FILING RECEIPT 



•OC000000025431186* 



Date Mailed: 08/20/2007 



Receipt is acknowledged of this nonprovisional patent application. The application will be taken up for 
examination in due course. Applicant will be notified as to the results of the examination. Any correspondence 
concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, 
FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are 
subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this 
Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections. Please 
provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File 
Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to 
the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing 
Receipt incorporating the requested corrections (if appropriate). 



Applicants) 

Giulio Superti-Fuga, Heidelberg, GERMANY; 
Ulrich Kruse, Dossenheim, GERMANY; 
Vladimir Rybin, Heidelberg, GERMANY; 
Gitte Neubauer, Mannheim, GERMANY; 

Power of Attorney: The patent practitioners associated with Customer Number 21559. 



Domestic Priority data as claimed by applicant 

This application is a 371 of PCT/EP04/04883 05/07/2004 
which claims benefit of 60/472,663 05/22/2003 



Foreign Applications 

EUROPEAN PATENT OFFICE (EPO) 03 10 0 274 . 4 05/07/2003 

030W2?0.f 

If Required, Foreign Filing License Granted: 08/16/2007 

The country code and number of your priority application, to be used for filing abroad under the Paris 
Convention, is US1 0/555,896 



Projected Publication Date: 11/22/2007 
Non-Publication Request: No 



Fage 2ol3 



Early Publication Request: No 
Title 

Process for the Identification of New Medical Targets 

Preliminary Class 

435 

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES 

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no 
effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in 
a specific country or in regional patent offices. Applicants may wish to consider the filing of an international 
application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same 
effect as a regular national patent application in each PCT-member country. The PCT process simplifies the 
filing of patent applications on the same invention in member countries, but does not result in a grant of "an 
international patent" and does not eliminate the need of applicants to file additional documents and fees in 
countries where patent protection is desired. 

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an 
application for patent in that country in accordance with its particular laws. Since the laws of many countries differ 
in various respects from the patent law of the United States, applicants are advised to seek guidance from 
specific foreign countries to ensure that patent rights are not lost prematurely. 

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO 
must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent 
application serves as a request for a foreign filing license. The application's filing receipt contains further 
information and guidance as to the status of applicant's license for foreign filing. 

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the 
section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign 
patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it 
can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html. 

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may 
wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce 
initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual 
property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement 
issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158). 



LICENSE FOR FOREIGN FILING UNDER 
Title 35, United States Code, Section 184 
Title 37, Code of Federal Regulations, 5.11 & 5.15 

GRANTED 

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING 
LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where 
the conditions for issuance of a license have been met, regardless of whether or not a license may be required as 
set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier 
license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The 



Fage 5 oi j 



date indicated is the effective date of the license, unless an earlier license of similar scope has been granted 
under 37 CFR 5.13 or 5.14. 

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof 
unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 
1.53(d). This license is not retroactive. 

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject 
matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the 
national security or the export of technical data. Licensees should apprise themselves of current regulations 
especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, 
Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of 
Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, 
Department of Treasury (31 CFR Parts 500+) and the Department of Energy. 

NOT GRANTED 

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING 
LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 
5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months 
has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy 
order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b). 



Exhibit 1 



ISENBRUCK | BOSL I HORSCHLER I WICHMANN I HUHN 

Patentanwalte 



Patentanwalte Postfach 860 880 0-81635 Munchen 

Europaisches Patentamt 
80298 Munchen 



Munchen, December 7, 2005 



EP 04731591.6 
CellZome AG 

Process for the identification of new medical targets 
Our ref: CEL62764PCEP HN/FLZ/smi 



I. Requests 

1. Entry of the national stage of the above application based on the at- 
tached documents is requested. 

2. Should the Receiving Section come to the conclusion that the above 
request has been filed too late, it is requested to issue a communication 
pursuant to R. 85a and 85b EPC. 

3. It is requested that the priority number be corrected from EP 
03100274.4 to EP 03010290.9 under R. 88 EPC. 

4. It is requested that the priority document EP 03010290.9 be included in 
the file according to R. 38 (4) EPC. 

5. Oral Proceedings according to Art. 116 EPC are requested should the 
Receiving Section be inclined to reject the request for correcting the 
priority number. 



II. Summary of the facts 



MANNHEIM 

Theodor-Heuss-Anlage 12 
68165 Mannheim 
Tel: -49 (621) 42 271-0 
Fax:-49 (621) 42 271-31 



MONCHEN 
Prinzregentenstr. 68 
81675 Munchen 
Tel: +49 (89) 99 88 54-0 
Fax: +49 (89) 99 88 54-99 



HEIDELBERG 

lm Neuenheimer Feld 582 

69120 Heidelberg 

Tel: +49 (6221) 65 303-30 

Fax: +49 (6221) 65 303-31 



0U5SELDORF 
Grafenberger Allee 342 
40235 Dusseldorf 
Tel: +49 (211) 15 77 56 □ 
Fax: +49 (211) 15 77 56-13 



EPO- Munich 
41 

0 f Dez, 2005 

Dr. Fritz Lahrtz 
Postfach 860 880 
81635 Munchen 

Tel. +49 (89) 998854-0 
Fax +49 (89) 998854-99 
lahrtz@ib-patent.de 

Patentanwalte 
European Patent Attorneys 
European Trade Mar* & 
Design Attorneys 

MANNHEIM 
GQnter Isenbruck 
Dr.phil.nat. - Oipl.-Chem. 

Wolfram Hbrschler 
Oipl.-lng. 

Alexander Schuck 
Or.rer.nat. ■ Oipl.-Chem. 

Hedwig Kern 
Dr.rer.nat. - Dipl.-lng. 

Arndl Ellwanger 
Dr.rer.nal. - Oipl.-Chem. 

Susanne Diel 
Dipl.-Phys. 

Edwin Buchel* 
Dr.rer.nat. - Oipl.-Chem. 

MUNCHEN 

Raphael Bosl 
Dr.rer.nal. - Dipl.-Chem. 

Hendrik Wichmann 
Dr.rer.nat. • Dipl.-Biol. 

Fritz Lahrtz 

Dr.rer.nat. - Dipl.-Natw. ETH 

Andreas Altmann 
Dr.rer.nat. - Oipl.-Chem. 

Andrea Teschemacher 
Or.rer.nat. - Dipl.-8iol. 

Daniela Kinkeldey 
Dr.rer.nat. - Dipl.-Chem. 

HEIDELBERG 

Michael Huhn 
Dr.rer.nal. - Dipl.-Chem. 

Alexander Dick 

Dr.rer.physiol. • Dipl.-Hum.-Bicl. 

D0SSELDORF 

Stefan Feaux de Lacroix 
Dr.rer.nat. - Oipl.-Chem. 

Dorothee Hollah 
Dr.rer.nat. • Dipl.-Chem. 

Patentanwalte 

European Trade Mark & 

Design Attorneys 
'European Patent Attorney 



VAT-Re9.N0. DE 226 569505 
US<-Nr. 38161/22616 

Email: inlo@ib-patent.de 
http://www.Ib-patent.de 



ISENBRUCK I BOSL I HORSCHLER I W1CHMANN I HUHN 

PQtsmanwiho 



1. According to instructions received on April 4, 2004, our finm filed the present PCT 
application on May 7, 2004, claiming, inter alia, the priority of EP 03100274.4, filed al- 
legedly on May 7, 2003. 

2. However, this number was incorrect, since the correct number should have been EP 
03010290.9, filed on May 7, 2003. This error resulted from the fact that the person han- 
dling patent matters at Cellzome AG had erroneously noted the incorrect number in his 
list of pending patent applications. 

3. The incorrect number, EP 03100274,4, corresponds to a patent application filed on Feb- 
ruary 10, 2003, relating to a completely different subject matter, namely to protein com- 
plexes of the TNFalpha signal transduction pathway. This application has more than 
1300 pages and is available to the Examiner by file inspection of the published PCT ap- 
plication WO 04/035783. Due to the size of this application, it is refrained from provid- 
ing it as paper copy. 

4. The correct priority document, EP 03010290.9 (copy attached) was filed, as correctly 
indicated in the PCT request, on May 7, 2003. Both EP applications were filed by an- 
other law firm in the name of Cellzome AG. 

5. On June 9, 2004, it was requested that the EPO should prepare and transmit to the Inter- 
national Bureau a certified copy of EP 03100274.4. 

6. On November 1 1, 2004, more than five months after the filing of the request indicated 
under 5. above and after the 16 months term as set in R. 26bis PCT, our firm received a 
notification of the EPO indicating an inconsistency between the filing date and the num- 
ber of the priority document. 

7. On December 9, 2004, a request for correction priority in the international phase was 
filed. Since the 16 months term had already passed, this request was rejected on Febru- 
ary 21, 2005. 



III. Correction of priority 

1 . The request for correcting the priority number is well founded. 

2. It is accepted case law that a priority claim may be corrected under R. 88 EPC also after 
entry of the regional phase before the EPO. The relevant case law and the respective re- 
quirements are e.g. summarized in J 02/92 and J 02/03. In fact, the present case resem- 
bles very much these t wo decisions, where also the correction of the priority number has 
been allowed. 

3. From the facts, there can be no doubt that the error for which correction is requested 
does not concern an omission in the priority declaration but an error and mistake con- 
cerning particulars of the priority declaration (See J 02/92, Point 4. of the Reasons). It is 
clear that it was intended to claim priority of EP 03010290.9, filed on May 7, 2003. Fur- 



Page 2 | CEL62764PCEP 



ISENBRUCK I BOSL I KORSCHLER i WICHMANN I 

PatentanwJIu 



thermore, a correction during the international phase was not possible due to the expiry 
of the time limit of R. 26bis PCT. 

t. At the date of the publication of the present PCT application (WO 04/99774) it would 
have been clear to the skilled person that the priority claim was incorrect, since he 
would have known from WO 04/035783 that EP 03100274.4 had been filed on Febru- 
ary 10, 2003 (i.e. more than one year before the filing of the present PCT application) 
and was directed to a different subject matter. 

>. Finally, the requested correction would not adversely affect the interests of Third Par- 
ties. As stated in J 02/92, there exists no substantial interest 

'7/7 maintaining a wrong file number in the published application. Third parties 
should inspect the file if they wish to draw substantive conclusions from the prior- 
ity document. In this respect, the file number as such is of no relevance to a com- 
petitor who has to make up his mind whether he may use the invention or not. A 
correction does not affect his interests (see Pont 5.2.3 of the Reasons). 

!. These conclusions have been confirmed in J 02/03 (see Pont 4.1 of the Reasons). 

In conclusion, the requirements as set forth in the case law for allowing a request for the 
correction of a priority number during the regional phase before the EPO are presently 
fulfilled. The request for correcting the priority number to EP 03010290.9 is well 
founded. 

The request to issue a communication pursuant to R. 85a and 85b EPC is only made in 
abundance of precaution in the unlikely case that the Receiving Section should come to 
the conclusion that regional phase should have been entered 31 months after the filing 
date of the incorrect priority document EP 03 1 00274.4. 




Dr. Fritz Lahrtz 
European Patent Attorney 



Attachment: 

Text of Priority document EP 0301 0290.9 



Page 3 | CEL62764PCEP 



(12) I NTK KNATIONA L APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY fPCT) 

Exhibit 2 

iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii 



(19) World Intellectual Property 
Organization 
Internationa] Bureau 




(43) Internationa) Publication Date 
18 November 2004 (18.11.2004) 



PCT 



(10) International Publication Number 

WO 2004/099774 A2 



(51) International Patent Classification 7 : G01N 33/53 

(21) International Application Number: 

PCT/EP20O4/0O4883 

(22) International Filing Date: 7 May 2004 (07.05.2004) 

(25) Filing Language: English 

(26) Publication Language: English 



(30) Priority Data: 
03100274.4 
60/472.663 



7 May 2003 (07.05.2003) l:P 
22 May 2003 (22.05.2003 ) US 



(71) Applicant (for all designated Stales except US): CELL- 
ZOME AG |DE/Di:|; Mcyerhofeirassc L 69117 Heidel- 
berg (Dl:). 

(72) Inventors; and 

(75) Inventors/Applicants (for US only): SUPERTI-FUGA, 
Giulio flT/Dfil; Muhldamm 7, 69118 Heidelberg (DE). 
KRUSE, Ulrich (DE/DE]; Frankenwee 32, 69221 Dossen- 
heim {DE). KYBIN, Vladimir [RU/DE]; Boxbergring 107, 
69126 Heidelberg (DE). NEUBAUER, Gilte [DE/DE]: 
Wilhelmsirasse 54, 68259 Mannheim (DE). 

(74) Agent: HUHN, Michael; Iscnbruck Bcisl Horschler YVi ch- 
in ann Wuhn, Theodor-Heuss-Anlage 12, 68165 Mannheim 
(DE). 



(81) Designated States (unless otherwise indicated, for every 
kind of national protection available): AE, AG, AL, AM, 
AT. AIL AZ. BA, BB 7 BG, BR, BW, BY. BZ, CA, CH, CN. 
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI. 
GB. GD, GE. GH. GM. HR. HU : ft), IL, IN, IS, JP, KE, 
KG. KP. KR, KZ. LC LK, LR, LS. LT, LU, LV, MA, MD. 
MG. MK. MN, MW, MX, MZ, NA, NL NO, NZ, OM, PCL 
PH, PL. PT. RO, RU, SC, SD, SE, SG, SK, SL, S Y TJ, I'M. 
TN, TR. Ti\ 17-, UA. UG, US, UZ, VC. VN, YU, ZA, ZM, 

zw. 

(84) Designated States (unless otherwise indicated, for every 
kind of regional protection available): ARIPO (BW. GH. 
GM. KE, LS, MW. MZ, NA, SD. SL. SZ. TZ. UG. ZM. 
ZW). Eurasian (AM. AZ, BY, KG. KZ. MD. RU. TJ. TM ). 
European (AT. BE. BCi. CH, CY. CZ. DE, DK. EE. ES. I I, 
FR, GB, GR. 11U, IE, IT. LU, MC, NL, PL, l y L RO. SE. SL 
SK, TR). OAPI (BP. BJ, CF. CG, CI, CM, GA, GN. GQ. 
GW, ML, MR, NE, SN, TD, TG). 

Published: 

— without international search report and to be republished 
upon receipt of that report 

For two- letter codes and other abbreviations, refer to the "Guid- 
ance Notes on Codes and Abbreviations" appearing at the begin- 
ning of each regular issue of the FCT Gazette. 



< 

i> 

ON 
ON 

o 



(54) Title: PROCESS FOR THE IDENTIFICATION OF NEW MEDICAL TARGETS 



O t 57 ) Abstract: The present invention relates to a process for the isolation and identification of pharmaceutical!)' relevant target 

O compounds (TC) from a sample, said sample being derived i'rom a living organism, wherein said target eompound(s) bind(s) lo a 

^ compound of interest (COI) under physiological conditions, said compound of interest (COD being associated with a given impaired 

£*S condition or disease. Furthermore, the present invention relates to a process for the identification of a pharmaceutical!)' etlective 

!5T compound useful for preventing and/or treating a given impaired condition or disease, wherein said compound is identified by us 

^ binding to a relevant target compound (TC) thai has been identified and isolated according lo the above mentioned process. 



Exhibit 3 



10/555896 

JCl4Rec'dPCT/PT0 07 NOV 2005 



Application Data Sheet 
Application Information 

Application number:: 

Filing Date:; 11/07/2005 
Application Type:: Regular 
Subject Matter:: Utility 
Suggested Classification:: 
Suggested Group Art Unit- 
CD-ROM or CD-R?:: None 
Number of CD disks:: 
Number of copies of CDs:: 
Sequence submission?:: 
Computer Readable Form (CRF)?:: 
Number of copies of CRF:: 
Title:: 

Attorney Docket Number- 
Request of Early Publication?:: 
Request of Non-Publication?:: 
Suggested Drawing Figure:: 
Total Drawing Sheets:: 
Small Entity?:: No 
Petition Included?:: 
Petition Type- 
Licensed US Govt. Agency:: 



PROCESS FOR THE IDENTIFICATION OF NEW 
MEDICAL TARGETS 

50125/107001 

No 

No 



Page 1 



Initial, November 7, 2005 



Contract or Grant Numbers:: 
Secrecy Order in Parent Appl.?:: 

Applicant Information 

Applicant Authority Type:: 

Primary Citizenship Country:: 

Status:: 

Given Name:: 

Middle Name:: 

Family Name:: 

Name Suffix:: 

City of Residence:: 

State or Province of Residence:: 

Country of Residence:: 

Street of mailing address:: 

City of mailing address:: 

State or Province of mailing address:: 

Country of mailing address:: 

Postal or Zip Code of mailing address:: 

Applicant Authority Type:: 
Primary Citizenship Country:: 
Status:: 
Given Name:: 
Middle Name:: 



No 

Inventor 
Italy 

Full Capacity 
Giulio 

SUPERTI-FUGA 

Heidelberg 

Germany 
Muhldamm 7 
Heidelberg 

Germany 
69118 

Inventor 
Germany 
Full Capacity 
Ulrich 



Page 2 



Initial, November 7, 2005 



Family Name:: 

Name Suffix:: 

City of Residence:: 

State or Province of Residence:: 

Country of Residence:: 

Street of mailing address:: 

City of mailing address:: 

State or Province of mailing address:: 

Country of mailing address:: 

Postal or Zip Code of mailing address:: 

Applicant Authority Type:: 

Primary Citizenship Country:: 

Status:: 

Given Name:: 

Middle Name:: 

Family Name:: 

Name Suffix:: 

City of Residence:: 

State or Province of Residence:: 

Country of Residence:: 

Street of mailing address:: 

City of mailing address:: 

State or Province of mailing address:: 

Country of mailing address:: 



KRUSE 

Dossenheim 

Germany 
Frankenweg 32 
Dossenheim 

Germany 
69221 

Inventor 

Russia 

Full Capacity 

Vladimir 

RYBIN 

Heidelberg 

Germany 
Boxbergring 107 
Heidelberg 

Germany 



Page 3 



Initial, November 7, 2005 



Postal or Zip Code of mailing address:: 69126 



Applicant Authority Type:: 
Primary Citizenship Country:: 
Status:: 
Given Name:: 
Middle Name:: 
Family Name- 
Name Suffix- 
City of Residence- 
State or Province of Residence- 
Country of Residence- 
Street of mailing address- 
City of mailing address:: 
State or Province of mailing address- 
Country of mailing address:: 
Postal or Zip Code of mailing address- 



Inventor 
Germany 
Full Capacity 
Gitte 

NEUBAUER 

Mannheim 

Germany 

Wilhelmstrasse 54 
Mannheim 

Germany 
68259 



Correspondence Information 

Correspondence Customer Number:: 21 559 

Representative Information 

Representative Customer Number:: 21 559 



Domestic Priority Information 



Application- 



Continuity Type: 



Parent Filing 
Parent Application:: Date- 



Page 4 



Initial, November 7, 2005 



This Application 



National stage of 



PCT/EP2004/004883 05/07/04 



PCT/EP2004/004883 An application claiming the 60/472,663 

benefit under 35 USC 1 19(e) 



05/22/03 



Foreign Priority Information 

Country:: Application Number:: 
EP 03010290.9 



Filing Date:: 
05/07/03 



Priority Claimed:: 
YES 



Assignee Information 

Assignee name:: 

Street of mailing address:: 

City of mailing address:: 

State of Province of mailing address:: 

Country of mailing address:: 

Postal or Zip Code of mailing address:: 



Page 5 Initial, November 7, 2005